U Durmus1, C Duran2, S Ecirli1. 1. Department of Internal Medicine, Konya Health Application and Research Center, University of Health Sciences, Meram Yeniyol, Meram, 42100, Konya, Turkey. 2. Division of Endocrinology and Internal Medicine, Konya Health Application and Research Center, University of Health Sciences, Meram Yeniyol, Meram, 42100, Konya, Turkey. drcduran@gmail.com.
Abstract
BACKGROUND: Visceral adiposity index (VAI) is a proposed parameter to evaluate visceral obesity instead of waist circumference (WC) in patients with polycystic ovary syndrome (PCOS). We aimed to evaluate VAI levels in overweight and/or obese, and non-obese PCOS patients and investigate the association between metabolic and inflammatory parameters. METHODS: Seventy-six PCOS patients between 18 and 40, and 38 age- and BMI-matched controls were enrolled into the study. Both PCOS groups and controls were classified into two subgroups according to body mass index (BMI) <25 and ≥25 kg/m2. RESULTS: In PCOS patients, waist/hip ratio (WHR) (p = 0.023), diastolic blood pressure (DBP) (p = 0.001), insulin (p = 0.011), homeostasis of model assessment (HOMA-IR) (p = 0.006) and uric acid (UA) (p = 0.002) were higher than controls. In overweight and/or obese PCOS group, DBP (p < 0.001), insulin (p = 0.002), HOMA-IR (p = 0.001), triglyceride (p = 0.015) and VAI (p = 0.031) were higher than overweight and/or obese controls. In non-obese PCOS group, WHR (p = 0.016), WC (p = 0.030), DBP (p = 0.010) and UA (p < 0.001) were higher than non-obese controls. Similar VAI levels were found in all PCOS and non-obese PCOS subgroups than peer controls. Overweight and/or obese PCOS group had higher VAI levels than non-obese PCOS group (p < 0.001). VAI levels were positively correlated with WHR, glucose, HOMA-IR, high-sensitive CRP and UA in PCOS group. In controls, VAI levels were positively correlated with WHR, insulin and HOMA-IR. CONCLUSION: We found that VAI levels were higher in overweight and/or obese PCOS patients compared to peer controls and non-obese PCOS patients, and associated with some metabolic and inflammatory parameters.
BACKGROUND: Visceral adiposity index (VAI) is a proposed parameter to evaluate visceral obesity instead of waist circumference (WC) in patients with polycystic ovary syndrome (PCOS). We aimed to evaluate VAI levels in overweight and/or obese, and non-obese PCOSpatients and investigate the association between metabolic and inflammatory parameters. METHODS: Seventy-six PCOS patients between 18 and 40, and 38 age- and BMI-matched controls were enrolled into the study. Both PCOS groups and controls were classified into two subgroups according to body mass index (BMI) <25 and ≥25 kg/m2. RESULTS: In PCOS patients, waist/hip ratio (WHR) (p = 0.023), diastolic blood pressure (DBP) (p = 0.001), insulin (p = 0.011), homeostasis of model assessment (HOMA-IR) (p = 0.006) and uric acid (UA) (p = 0.002) were higher than controls. In overweight and/or obese PCOS group, DBP (p < 0.001), insulin (p = 0.002), HOMA-IR (p = 0.001), triglyceride (p = 0.015) and VAI (p = 0.031) were higher than overweight and/or obese controls. In non-obese PCOS group, WHR (p = 0.016), WC (p = 0.030), DBP (p = 0.010) and UA (p < 0.001) were higher than non-obese controls. Similar VAI levels were found in all PCOS and non-obese PCOS subgroups than peer controls. Overweight and/or obese PCOS group had higher VAI levels than non-obese PCOS group (p < 0.001). VAI levels were positively correlated with WHR, glucose, HOMA-IR, high-sensitive CRP and UA in PCOS group. In controls, VAI levels were positively correlated with WHR, insulin and HOMA-IR. CONCLUSION: We found that VAI levels were higher in overweight and/or obese PCOSpatients compared to peer controls and non-obese PCOSpatients, and associated with some metabolic and inflammatory parameters.
Authors: Manuel Luque-Ramírez; Francisco Alvarez-Blasco; Miguel Giovanni Uriol Rivera; Héctor F Escobar-Morreale Journal: Hum Reprod Date: 2008-03-27 Impact factor: 6.918
Authors: Ricardo Azziz; Enrico Carmina; ZiJiang Chen; Andrea Dunaif; Joop S E Laven; Richard S Legro; Daria Lizneva; Barbara Natterson-Horowtiz; Helena J Teede; Bulent O Yildiz Journal: Nat Rev Dis Primers Date: 2016-08-11 Impact factor: 52.329
Authors: Susana Borruel; José F Moltó; Macarena Alpañés; Elena Fernández-Durán; Francisco Álvarez-Blasco; Manuel Luque-Ramírez; Héctor F Escobar-Morreale Journal: PLoS One Date: 2014-12-05 Impact factor: 3.240
Authors: A L L Rocha; L C Faria; T C M Guimarães; G V Moreira; A L Cândido; C A Couto; F M Reis Journal: J Endocrinol Invest Date: 2017-06-13 Impact factor: 4.256
Authors: S Behboudi-Gandevani; F Ramezani Tehrani; R Bidhendi Yarandi; M Noroozzadeh; M Hedayati; F Azizi Journal: J Endocrinol Invest Date: 2017-03-22 Impact factor: 4.256
Authors: Y Zhang; D Dilimulati; D Chen; M Cai; H You; H Sun; X Gao; X Shao; M Zhang; S Qu Journal: J Endocrinol Invest Date: 2022-07-05 Impact factor: 5.467
Authors: Viktor V Smirnov; Narasimha M Beeraka; Dmitry Yu Butko; Vladimir N Nikolenko; Sergey A Bondarev; Evgeniy E Achkasov; Mikhail Y Sinelnikov; P R Hemanth Vikram Journal: Reprod Sci Date: 2022-06-28 Impact factor: 2.924
Authors: J Rodríguez-Castelán; M Méndez-Tepepa; Y Carrillo-Portillo; A Anaya-Hernández; J Rodríguez-Antolín; E Zambrano; F Castelán; E Cuevas-Romero Journal: Biomed Res Int Date: 2017-01-04 Impact factor: 3.411